Skip to main content
Equibles

MARSHALL WACE, LLP

Position in EXEL — Exelixis, Inc.

CIK 1318757 LONDON, X0
Back to EXEL Full portfolio

Position in EXEL

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$45,242,240
+$32,374,683 QoQ
Shares Held
831,506
+177.2% QoQ
Ownership
0.336%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#51
of 756 holders
Holding Since
Jun 2020
16 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in EXEL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. EXEL ranks #19 (1.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 543,897 $270,169,956
2 INCY
Incyte Corp
 1,310,154 $148,519,056
3 RPRX
Royalty Pharma plc
 2,450,669 $137,409,009
4 SYRE
Spyre Therapeutics, Inc.
 991,693 $88,042,503
5 ALNY
Alnylam Pharmaceuticals, Inc.
 259,799 $78,207,292
6 TVTX
Travere Therapeutics, Inc.
 1,333,207 $75,739,488
7 MANE
Veradermics, Inc
 585,560 $71,988,746
8 DFTX
Definium Therapeutics, Inc.
 1,298,946 $61,102,419

All Filings in EXEL

Export CSV
16 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $45,242,240 831,506
2026-03-31 $12,867,557 300,013
2025-06-30 $6,950,445 157,678
2024-12-31 $11,264,857 338,284
2024-09-30 $9,721,155 374,611
2024-06-30 $800,920 35,644
2023-09-30 $371,450 17,000
2023-06-30 $4,558,824 238,557
2023-03-31 $8,341,039 429,729
2022-12-31 $5,985,181 373,141
2022-09-30 $1,356,962 86,541
2022-06-30 $11,724,637 563,143
2022-03-31 $28,245,617 1,245,947
2021-12-31 $4,001,071 218,877
2021-09-30 $13,089,782 619,195
2020-06-30 $3,033,829 127,794